PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development

Toxicologic Pathology

Volumn 43, Issue 7, 2015, Pages 959-983

  Ivens, Inge A ^a   Achanzar, William ^b   Baumann, Andreas ^c   Brändli Baiocco, Annamaria ^d   Cavagnaro, Joy ^e   Dempster, Maggie ^f   Depelchin, B Olympe ^g   Irizarry Rovira, Armando R ^h   Dill Morton, Laura ⁱ   Lane, Joan H ^j   Reipert, Birgit M ^k   Salcedo, Theodora ^l   Schweighardt, Becky ^m   Tsuruda, Laurie S ^m   Turecek, Peter L ^k   Sims, Jennifer ⁿ  

^a BAYER CORPORATION   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c BAYER PHARMA AG   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

^e Access BIO   (United States)

^f GLAXOSMITHKLINE   (United States)

^g UCB PHARMA   (Belgium)

^h ELI LILLY AND COMPANY   (United States)

ⁱ NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^j BIOGEN   (United States)

^k Baxalta Innovations GmbH   (Austria)

^l JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^m BIOMARIN PHARMACEUTICAL INC   (United States)

ⁿ Integrated Biologix GmbH   (Switzerland)

more..

Author keywords

biopharmaceutical; nonclinical; PEG; PEGylation; polyethylene glycol; toxicology; vacuolation

Indexed keywords

BIOLOGICAL MARKER; BIOLOGICAL PRODUCT; MACROGOL; PEGYLATED BIOPHARMACEUTICALS; PEGYLATED PROTEIN; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; MACROGOL DERIVATIVE;

AGE RELATED MACULAR DEGENERATION; CELL FUNCTION; CELL VACUOLE; CHOROID PLEXUS; COVALENT BOND; DRUG CONTROL; DRUG INDICATION; DRUG INDUSTRY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; KIDNEY FUNCTION; LIVER FUNCTION; MACROPHAGE FUNCTION; MULTIPLE SCLEROSIS; MUSCLE ATROPHY; MUSCLE FUNCTION; NERVOUS SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEGYLATION; PHAGOCYTE; PHARMACEUTICAL ENGINEERING; PRIORITY JOURNAL; RENAL CLEARANCE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SPLEEN FUNCTION; TOXICITY TESTING; ANIMAL; CHEMISTRY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; PRECLINICAL STUDY;

ANIMALS; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; POLYETHYLENE GLYCOLS;

EID: 84942918124     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623315591171     Document Type: Review

References (63)

1. Abbott N. J., Ronnback L., Hansson E., (2006). Astrocyte-endothelial interactions at the blood-brain barrier, 40CFR Part 261. U.S. Government Printing Office, Washington, DC.
2. Armstrong J. K., Hempel G., Koling S., Chan L. S., Fisher T., Meiselman H. J., Garratty G., (2007). Antibody against poly (ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110, 103-11.
3. Bachmann M. F., Zinkernagel R. M., (1997). Neutralizing antiviral B cell responses. Annu Rev Immunol 15, 235-70.
4. Baumann A., Tuerck D., Prabhu S., Dickmann L., Sims J., (2014). Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: Quo vadis? Drug discov Today 19, 1623-31.
5. Bendele A., Seely J., Richey C., Sennello G., Shopp G., (1998). Short communication: Renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol Sci 42, 152-57.
6. Caliceti P., Veronese F. M., (2003). Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55, 1261-77.
7. Cheng T. L., Chuang K. H., Chen B. M., Roffler S. R., (2012). Analytical measurement of PEGylated molecules. Bioconjug Chem 23, 881-99.
8. CHMP Safety Working Party of the European Medicinal Agency. (2012). EMA's paediatric committee regarding the use of PEGylated drug products in the pediatric population intended for long-term treatment. November 16, 2012. EMA/CHMP/SWP/647258/2012. Accessed April 2015, http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/2011/WC500135123.pdf.
9. Chtourou S., (2012). Chapter 2: Production and clinical profile of human plasma coagulation factor VIII. In Production of Plasma Proteins for Therapeutic Use (Bertolini J., Goss N., Curling J., eds.), pp. 30-40. John Wiley.
10. Dorato M. A., Engelhardt J. A., (2005). The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s). Regul Toxicol Pharmacol 42, 265-74.
11. Dreborg S., Akerblom E. B., (1990). Immunotherapy with monomethoxypolyethylene glycol modified allergens. Crit Rev Ther Drug Carrier Syst 6, 315-65.
12. Food and Drug Administration. (2014). FDA Guidance for Industry: Immunogenicity Assessment of Therapeutic Protein Products. Accessed April 15, http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm338856.pdf.
13. Ganson N. J., Kelly S. J., Scarlett E., Sundy J. S., Hershfield M. S., (2006). Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly (ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8, R12.
14. Garay R. P., El-Gewely R., Armstrong J. K., Garratty G., Richette P., (2012). Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Del 9, 1319-23.
15. Garratty G., (2004). Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs. Transfus Med Rev 18, 245-56.
16. Garratty G., (2008). Modulating the red cell membrane to produce universal/stealth donor red cells suitable for transfusion. Vox Sang 94, 87-95.
17. Hamidi M., Azadi A., Rafiei P., (2006). Pharmacokinetic consequences of pegylation. Drug Deliv 13, 399-409.
18. Hershfield M. S., Ganson N. J., Kelly S. J., Scarlett E. L., Jaggers D. A., Sundy J. S., (2014). Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther 16, R63.
19. Hirota K. A.T. H., (2012). Endocytosis of particle formulations by macrophages and its application to clinical treatment. Biochem Genet Mol Biol. Accessed April 2015, http://medicaltextboks.blogspot.com/2013/03/TEXTBOOK-MOLECULAR-REGULATION-OF-ENDOCYTOSIS.html.
20. ICH (International Conference on Harmonization S6 R1). (2011). Preclinical safety evaluation of biotechnology-derived pharmaceuticals, 40CFR Part 261. U.S. Government Printing Office, Washington, DC.
21. Ivens I. A., Baumann A., McDonald T. A., Humphries T. J., Michaels L. A., Mathew P., (2013). PEGylated therapeutic proteins for haemophilia treatment: A review for haemophilia caregivers. Haemophilia 19, 11-20.
22. Jevsevar S., Kunstelj M., Porekar V. G., (2010). PEGylation of therapeutic proteins. Biotechnol J 5, 113-28.
23. Judge A., McClintock K., Phelps J. R., Maclachlan I., (2006). Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 13, 328-37.
24. Kang J. S., Deluca P. P., Lee K. C., (2009). Emerging PEGylated drugs. Expert Opin Emerg Drugs 14, 363-80.
25. Kelly S. J., Delnomdedieu M., Oliverio M. I., Williams L. D., Saifer M. G., Sherman M. R., Coffman T. M., Johnson G. A., Hershfield M. S., (2001). Diabetes insipidus in uricase-deficient mice: A model for evaluating therapy with poly (ethylene glycol)-modified uricase. J Am Soc Nephrol 12, 1001-9.
26. Kindt T. J., Osborne B. A., Golds R. A., (2006). Chapter 15: Hypersensitivity reactions. In Kuby Immunology edition 6. Freeman, W. H. & Company, New York, 2006,. ISBN-13: 9781429202114.
27. Kronenberg S., Baumann A., de Haan L., Hinton H. J., Moggs J., Theil F. P., Wakefield I., Singer T., (2013). Current challenges and opportunities in nonclinical safety testing of biologics. Drug Discov Today 18, 1138-43.
28. Liddelow S. A., (2015). Development of the choroid plexus and blood-CSF barrier. Front Neurosci 9, 32.
29. Longley C. B., Zhao H., Lozanguiez Y. L., Conover C. D., (2013). Biodistribution and excretion of radiolabeled 40 kDa polyethylene glycol following intravenous administration in mice. J Pharm Sci 102, 2362-70.
30. Mehvar R., (2000). Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J Pharm Pharm Sci 3, 125-36.
31. Mitchison N. A., (1971). The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur J Immunol 1, 18-27.
32. Mond J. J., Lees A., Snapper C. M., (1995). T cell-independent antigens type 2. Annu Rev Immunol 13, 655-92.
33. Muller H. J., Loning L., Horn A., Schwabe D., Gunkel M., Schrappe M., von Schutz V., et al. (2000). Pegylated asparaginase (Oncaspar) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 110, 379-84.
34. Nakaoka R., Tsuchiya T., Kato K., Ikada Y., Nakamura A., (1997). Studies on tumor-promoting activity of polyethylene: Inhibitory activity of metabolic cooperation on polyethylene surfaces is markedly decreased by surface modification with collagen but not with RGDS peptide. J Biomed Mater Res 35, 391-97.
35. Oh N., Park J. H., (2014). Endocytosis and exocytosis of nanoparticles in mammalian cells. Int J Nanomedicine 9, 51-63.
36. Parihar A., Eubank T. D., Doseff A. I., (2010). Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death. J Innate Immun 2, 204-15.
37. Polson A., (1976). Influenza virus vaccine. In United States Patent 3989818,. November 2, 1976.
38. Reipert B. M., Lubich C., Weiller M., Allacher P., Siekmann J., de la Rosa M., Scheiflinger F., Schwarz H. P., Horling F. M., (2012). Does PEGylated factor VIII induce antibodies against PEG? Hemophilia 18, 28-29. (abstract).
39. Richter A. W., Akerblom E., (1983). Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 70, 124-31.
40. Richter A. W., Akerblom E., (1984). Polyethylene glycol reactive antibodies in man: Titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int Arch Allergy Appl Immunol 74, 36-39.
41. Roberts M. J., Bentley M. D., Harris J. M., (2002). Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54, 459-76.
42. Rock K. L., Benacerraf B., Abbas A. K., (1984). Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med 160, 1102-13.
43. Rudmann D. G., Alston J. T., Hanson J. C., Heidel S., (2013). High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol Pathol 41, 970-83.
44. Saenger S., Goeldner C., Frey J. R., Ozmen L., Ostrowitzki S., Spooren W., Ballard T. M., Prinssen E., Borroni E., Metzger F., (2011). PEGylation enhances the therapeutic potential for insulin-like growth factor I in central nervous system disorders. Growth Horm IGF Res 21, 292-303.
45. Schellekens H., Hennink W. E., Brinks V., (2013). The immunogenicity of polyethylene glycol: Facts and fiction. Pharm Res 30, 1729-34.
46. Schrappe M., Camitta B., Pui C. H., Eden T., Gaynon P., Gustafsson G., Janka-Schaub G. E., et al. (2000a). Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 14, 2193-94.
47. Schrappe M., Reiter A., Ludwig W. D., Harbott J., Zimmermann M., Hiddemann W., Niemeyer C., et al. (2000b). Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 95, 3310-22.
48. Schrappe M., Reiter A., Zimmermann M., Harbott J., Ludwig W. D., Henze G., Gadner H., Odenwald E., Riehm H., (2000c). Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 14, 2205-22.
49. Strazielle N., Ghersi-Egea J. F., (2013). Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol Pharmaceut 10, 1473-91.
50. Sundy J. S., Baraf H. S., Yood R. A., Edwards N. L., Gutierrez-Urena S. R., Treadwell E. L., Vazquez-Mellado J., et al. (2011). Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA 306, 711-20.
51. Takahashi K., (2001). Development and differentiation of macrophages and related cells: Historical review and current concepts. J Clin Exp Hematop 41, 33.
52. Takao O., Fujiwara T., Ohmizu A., Funakoshi S., (1986). Process for producing a hepatitis B infection prevention vaccine. In United States Patent 4565697,. January 21, 1986.
53. Ton N. C., Parker G. J., Jackson A., Mullamitha S., Buonaccorsi G. A., Roberts C., Watson Y., et al. (2007). Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res 13, 7113-18.
54. van Helden P. M., Unterthurner S., Hermann C., Schuster M., Ahmad R. U., Schiviz A. N., Weiller M., et al. (2011). Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model. Blood 118, 3698-707.
55. Verhoef J. J., Carpenter J. F., Anchordoquy T. J., Schellekens H., (2014). Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today 19, 1945-52.
56. Veronese F. M., Mero A., (2008). The impact of PEGylation on biological therapies. BioDrugs 22, 315-29.
57. Veronese F. M., Pasut G., (2005). PEGylation, successful approach to drug delivery. Drug Discov Today 10, 1451-58.
58. Wang H., Wang L., Cao K., Emanuel S. L., Morin P., Lin Z., Shen G., et al. (2012). Development of a carbon-14 labeling approach to support disposition studies with a pegylated biologic. Drug Metab Dispos 40, 1677-85.
59. Webster R., Didier E., Harris P., Siegel N., Stadler J., Tilbury L., Smith D., (2007). PEGylated proteins: Evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 35, 9-16.
60. Webster R., Elliott V., Park B. K., Walker D., Hankin M., Taupin P., eds. (2009). PEG and PEG Conjugates Toxicity: Towards an Understanding of the Toxicity of PEG and its Relevance to PEGylated Biologicals. Birkhäuser Verlag, Basel, Switzerland.
61. Yamaoka T., Tabata Y., Ikada Y., (1994). Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 83, 601-6.
62. Yamaoka T., Tabata Y., Ikada Y., (1995). Comparison of body distribution of poly (vinyl alcohol) with other water-soluble polymers after intravenous administration. J Pharm Pharmacol 47, 479-86.
63. Yu D., Zhao Y., Choe Y. H., Zhao Q., Hsieh M.-C., Peng P., (2004). Cellular penetration and localization of polyethylene glycol. Proc Amer Assoc Cancer Res 45, a644.